EUVIMEDEUVIMED entdecken
Crossref

Management of Oral Anticoagulant-associated Intracerebral Hemorrhage

Corina Epple, Thorsten Steiner

Journal of Stroke Medicine · 2018

DOI: 10.1177/2516608518821745 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Stroke Medicine, 2018. Verfasst von Corina Epple und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 74 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Oral anticoagulant-associated intracerebral hemorrhages (OAC-ICHs) account for nearly 20% of all ICH and are associated with high mortality. The number of patients with an indication for oral anticoagulant therapy (OAT) is increasing with the aging population; therefore, despite the improved safety profile of non-vitamin K oral anticoagulants (NOACs), the number of patients with OAC-ICH will increase. OAT was simplified with the introduction of NOACs, which are easy to handle and show a favorable risk-benefit profile. The rate of ICH is lower than for vitamin K antagonists (VKA) and routine coagulation testing is not required. Nevertheless, OAC-ICH does occur and is still a devastating disease, thus representing the most feared complication in OAT, irrespective of treatment with VKA or NOAC.

Purpose

The aim of this article is to address the clinical problem of bleeding management in patients with ICH due to OAC and will consider anticoagulation with NOAC and VKA. Recommendations: Restoring coagulation as soon as possible is the main goal and, therefore, knowledge of the actual coagulation status is essential. In VKA-associated ICH, the international normalized ratio (INR) should be lowered to below 1.3. However, laboratory measurement of anticoagulant activity in NOAC patients is more complex, rendering OAC-ICH treatment more complicated. The best assays are specialized and not widely available, whereas more accessible tests such as prothrombin time and activated partial thromboplastin time have important limitations. For VKA-ICH, prothrombin complex concentrate (PCC) should be administered to reverse the INR. For dabigatran-related ICH, 5 g idarucizumab should be administered. For factor Xa inhibitors, PCC is recommended in the absence of andexanet alfa as soon as an OAC-related ICH evolves. Resuming OAC after ICH should be considered, depending on risk factors and a risk-benefit evaluation.

Zitieren

APA

Epple, C., & Steiner, T. (2018). Management of Oral Anticoagulant-associated Intracerebral Hemorrhage. Journal of Stroke Medicine. https://doi.org/10.1177/2516608518821745

Vancouver

Epple C, Steiner T. Management of Oral Anticoagulant-associated Intracerebral Hemorrhage. Journal of Stroke Medicine. 2018. doi:10.1177/2516608518821745

BibTeX
@article{Epple2018,
  author = {Epple, Corina and Steiner, Thorsten},
  title = {Management of Oral Anticoagulant-associated Intracerebral Hemorrhage},
  journal = {Journal of Stroke Medicine},
  year = {2018},
  doi = {10.1177/2516608518821745}
}
Kostenlos starten →